Drug Watch: Tesamorelin Update
Table of Contents
Since it first became available in the mid-1990s, highly active antiretroviral therapy (HAART) has saved lives and improved health and quality of life for countless people living with HIV -- but the drugs are not without their downsides. One of these became clear within a few years after HAART was introduced, when people taking the new drugs began to experience dramatic and disturbing body shape changes caused by shifts in where fat accumulates.
Tesamorelin (brand name Egrifta), a new treatment to reduce one type of fat accumulation linked with antiretroviral treatment, has been in the works for a few years and was approved by the Food and Drug Administration (FDA) on November 11, 2010. This article explains how tesamorelin works, and why it represents an important development in HIV medicine.
Fat, also called "adipose tissue," can be stored subcutaneously (just below the skin) or more deeply. Loss of subcutaneous fat from the face, arms, legs and buttocks is collectively called "lipoatrophy." Fat accumulation, or "lipohypertrophy," can occur in the breasts (in both men and women), in the upper back and at the base of the neck (known as "buffalo hump") and in the belly. This kind of deep belly fat is known as "visceral adipose tissue" (VAT) -- in other words, fat (adipose tissue) that surrounds the abdominal organs (viscera).
Lipohypertrophy (abdominal obesity, in particular) is linked to metabolic issues such as insulin resistance (a pre-cursor to diabetes), hypertriglyceridemia (abnormally high levels of certain fats in the blood), decreased HDL ("good") cholesterol and cardiovascular disease. And the emotional pain and stigma around VAT are not inconsequential.
Clinicians and researchers are still trying to understand exactly what causes lipohypertrophy. Unlike lipoatrophy, which can be traced to specific antiretrovirals, fat accumulation is seen in individuals on a variety of treatment regimens. Duration of anti-HIV therapy is implicated, as is progression to AIDS, but so are other risk factors unrelated to HIV or its treatment, including older age and body composition before taking anti-HIV drugs.
Neither is it clear just how many people on HIV treatment have some form of lipodystrophy -- reports range from 11% to as high as 83%.
What is clear, however, is that the health risks and emotional distress caused by these body shape changes are severe enough to discourage some people from adhering to their treatment regimen, or from starting antiretroviral therapy at all. That's one reason why HIV treatment advocates have been rooting for a safe and effective drug to treat lipodystrophy -- and why the approval of tesamorelin is good news.
Experimental treatments for lipohypertrophy have focused largely on growth hormone products. Growth hormone is a chemical produced by the pituitary gland, located at the base of the brain. It stimulates gluconeogenesis -- production of glucose by the liver -- and also prompts the liver to secrete a protein called "insulin-like growth factor-1" (IGF-1). The production of this protein stimulates growth during childhood and continues to promote cell growth throughout the body in adulthood. Growth hormone is therefore critical for maintaining muscle and bone mass, and it also affects fat distribution in the body.
HIV positive men with VAT have been reported to have lower levels of growth hormone than HIV negative men or positive men without abdominal fat accumulation. Numerous studies have linked growth hormone levels with decreases in VAT.
One growth hormone product, called somatropin and marketed as Serostim, is FDA-approved for treatment of AIDS wasting (defined as loss of 10% of body weight, along with other symptoms), and has been used off-label to reduce VAT without simultaneously decreasing subcutaneous fat. While the treatment was found to be effective in clinical trials, side effects (including swelling, limb pain and elevated blood glucose) are problematic for some individuals, and the drug has not been approved to specifically treat abdominal fat accumulation.
Tesamorelin, developed by the Canadian pharmaceutical company Theratechnologies and referred to in research studies as TH9507, is a growth hormone product -- specifically, a growth hormone-releasing factor analog. Tesamorelin is not exactly growth hormone; rather, it stimulates the pituitary gland to secrete growth hormone.
A Phase II study of tesamorelin, described in the August 12, 2005, issue of the journal AIDS, enrolled 61 patients in three groups: placebo or 1 mg or 2 mg tesamorelin injected once daily. Visceral fat decreased by nearly 16% in the 2-mg treatment group (without a decrease in limb fat), and lean body mass increased in the tesamorelin groups compared with the placebo group. Cholesterol and triglyceride levels also went down in the treatment group. The treatment was found to be generally well tolerated, with no effect on blood glucose levels.
Subsequently, a Phase III study described at the 2007 Conference on Retroviruses and Opportunistic Infections and subsequently published in the New England Journal of Medicine examined the effect of tesamorelin on HIV-associated abdominal fat accumulation. In a press conference, investigator Steven Grinspoon, M.D., of Harvard Medical School's Division of Nutrition stressed the need for treatments to decrease VAT as a way of reducing cardiovascular disease risk for people living with HIV.
In this larger study, 412 participants were randomized in to receive 2 mg tesamorelin or placebo once daily. At 26 weeks, a 15.2% reduction in VAT was seen in the tesamorelin group, compared with a 5% increase in VAT in the placebo group. Waist circumference decreased by three centimeters on average in the tesamorelin group -- approximately one pants size, said Dr. Grinspoon.
Lipid profiles also improved in the treatment group, and the researchers reported no increase in glucose levels. Adverse events included headaches and arthralgias (joint pain) in more than 10% of participants in both groups, and swelling in the limbs, muscle aches and allergic rashes were slightly more common in the treatment group.
More recently, in the March 1, 2010, issue of JAIDS, Julian Falutz, M.D., of McGill University School of Medicine and colleagues described results from a 12-month Phase III safety and efficacy study of tesamorelin for reduction of VAT.
A total of 404 HIV positive participants on HAART and with excess abdominal fat were enrolled in the two-phase study. In the primary efficacy phase (the first six months), individuals were randomly assigned to receive either tesamorelin (2 mg injected subcutaneously once daily) or a placebo injection. In the extension phase (months 6-12), participants who originally received tesamorelin were re-randomized to either continue on tesamorelin (at the same dose) or switch to placebo. Those who were initially randomized to the placebo group were started on tesamorelin.
The results were encouraging: VAT decreased by 10.9% (a loss of 21 cm2) in the tesamorelin group compared with only 0.6% (a reduction of 1 cm2) in the placebo group in the first six months. In participants who continued on tesamorelin for 12 months, VAT declined by approximately 18%. IGF-1 levels also increased significantly.
Trunk fat, waist circumference and waist-to-hip ratio -- further measures of abdominal fat accumulation that are predictors of cardiovascular disease -- improved in the tesamorelin group, with no loss of subcutaneous fat in the abdomen and no limb fat reduction. As described at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, held in Boston in September 2010, study participants were asked to rate their "belly appearance distress"; this measure improved significantly, as did physician's ratings of belly profile, in the tesamorelin groups compared with those receiving placebo.
Importantly, the researchers observed, "these benefits occurred without any significant increases in glucose or insulin levels, a major concern for any strategy to augment [growth hormone] secretion in the HIV population."
The investigators reported that tesamorelin was well tolerated, although more adverse events were experienced by the tesamorelin-treated participants than by those on placebo. Adverse events were similar to those seen in earlier studies, with injection site reactions (including redness and itching) topping the list for both tesamorelin and placebo recipients -- although they occurred more frequently with tesamorelin.
One frequent criticism of clinical trials of new drugs is that the study sample fails to represent the larger population of people who need the treatments most; not every person who will want to use tesamorelin is white, male and free of hepatitis, for example. In an effort to address this common shortcoming, Monica Zoltowska, Ph.D., from Theratechnologies and colleagues performed a sub-group analysis using data from the two Phase III trials of tesamorelin. They examined the growth hormone product's safety and efficacy among trial participants grouped by age, sex, race/ethnicity, use of anti-HIV drugs, HIV viral load, and whether they also had hepatitis B or C.
At 26 weeks, the researchers reported, the effect of tesamorelin on VAT in the five sub-groups was consistent with that seen across the broader sample of participants in the two studies. No important differences in adverse events were detected throughout the full 52-week study. These data suggest that tesamorelin "reduces VAT in different sub-populations of HIV-infected patients with lipohypertrophy, without any clinically meaningful differences in long-term safety," the researchers concluded.
This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)